LIGHTPATH TECHNOLOGIES INC - Quarter Report: 2020 September (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
[X]
QUARTERLY REPORT
UNDER SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30,
2020
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
For the
transition period from ___________ to ____________
Commission file number 000-27548
LIGHTPATH TECHNOLOGIES, INC.
___________________________________________________
(Exact name of registrant as specified in its
charter)
DELAWARE
|
86-0708398
|
(State or other jurisdiction of
incorporation or
organization)
|
(I.R.S.
Employer Identification
No.)
|
http://www.lightpath.com
2603 Challenger Tech Ct. Suite 100
Orlando, Florida 32826
_________________________________________
(Address of principal executive offices)
(ZIP Code)
(407) 382-4003
________________________________
(Registrant’s telephone number, including area
code)
N/A
_______________________________________________________________________
(Former name, former address, and former fiscal year, if changed
since last report)
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Class A Common
Stock, par value $0.01
|
LPTH
|
The Nasdaq Stock Market, LLC
|
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days. YES [X] NO [ ]
Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (§232.405 of this
chapter) during the preceding 12 months (or such shorter period
that the registrant was required to submit such
files).
YES [ X ] NO [ ]
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, a
smaller reporting company, or an emerging growth company. See the
definitions of “large accelerated filer,”
“accelerated filer,” “smaller reporting
company,” and “emerging growth company” in Rule
12b-2 of the Exchange Act.
Large accelerated filer [
]
|
Accelerated
filer [ ]
|
|
Smaller
reporting company [ X ]
|
Non-accelerated filer [ X
]
|
Emerging
growth company [ ]
|
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act [
]
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act). YES [ ] NO
[X]
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the
issuer’s classes of common stock, as of the latest
practicable date:
26,109,225 shares of common stock, Class A, $0.01 par value,
outstanding as of November 2, 2020.
LIGHTPATH TECHNOLOGIES, INC.
Form 10-Q
Index
Item
|
|
Page
|
|
|
|
3
|
||
|
|
|
4
|
||
|
|
|
4
|
||
|
4
|
|
|
5
|
|
|
6
|
|
|
7
|
|
|
8
|
|
|
|
|
18
|
||
|
20
|
|
|
Liquidity and Capital Resources |
21
|
|
22
|
|
|
22
|
|
|
22
|
|
|
25
|
|
25
|
||
|
|
|
26
|
||
|
|
|
26
|
||
26
|
||
26
|
||
26
|
||
26
|
||
27
|
||
|
|
|
|
29
|
CAUTIONARY NOTE CONCERNING
FORWARD-LOOKING STATEMENTS
Certain statements and information in this Quarterly Report on Form
10-Q for the quarter ended September 30, 2020 (the “Quarterly
Report”) may constitute “forward-looking
statements” within the meaning of Section 27A of the
Securities Act of 1933, as amended (the “Securities
Act”), Section 21E of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), and the Private
Securities Litigation Reform Act of 1995. All statements, other
than statements of historical facts, which address activities,
events, or developments that we expect or anticipate will or may
occur in the future, including such things as future capital
expenditures, growth, product development, sales, business
strategy, statements related to the expected effects on our
business from the coronavirus (“COVID-19”) pandemic,
and other similar matters are forward-looking statements. In some
cases, you can identify forward-looking statements by terminology
such as “may,” “will,”
“should,” “expect,” “plan,”
“anticipate,” “believe,”
“estimate,” “predict,”
“potential,” or “continue,” or other
comparable terminology. These forward-looking statements are based
largely on our current expectations and assumptions and are subject
to a number of risks and uncertainties, many of which are beyond
our control. These statements are subject to many risks,
uncertainties, and other important factors that could cause actual
future results to differ materially from those expressed in the
forward-looking statements including, but not limited to, the
duration and scope of the COVID-19 pandemic and impact on the
demand for our products; our ability to obtain needed raw materials
and components from our suppliers; actions governments, businesses,
and individuals take in response to the pandemic, including
mandatory business closures and restrictions on onsite commercial
interactions; the impact of the pandemic and actions taken in
response to the pandemic on global and regional economies and
economic activity; the pace of recovery when the COVID-19 pandemic
subsides; general economic uncertainty in key global markets and a
worsening of global economic conditions or low levels of economic
growth; the effects of steps that we could take to reduce operating
costs; our inability to sustain profitable sales growth, convert
inventory to cash, or reduce our costs to maintain competitive
prices for our products; circumstances or developments that may
make us unable to implement or realize the anticipated benefits, or
that may increase the costs, of our current and planned business
initiatives; and those factors detailed by us in our public filings
with the Securities and Exchange Commission (the
“SEC”), including in Item 1A, Risk Factors, in our
Annual Report on Form 10-K for the year ended June 30, 2020. In
light of these risks and uncertainties, all of the forward-looking
statements made herein are qualified by these cautionary statements
and there can be no assurance that the actual results or
developments anticipated by us will be realized. We undertake no
obligation to update or revise any of the forward-looking
statements contained herein.
3
Item 1. Financial Statements
|
September
30,
|
June
30,
|
Assets
|
2020
|
2020
|
Current
assets:
|
|
|
Cash
and cash equivalents
|
$5,386,587
|
$5,387,388
|
Trade
accounts receivable, net of allowance of $10,153 and
$9,917
|
6,258,927
|
6,188,726
|
Inventories,
net
|
9,647,434
|
8,984,482
|
Other
receivables
|
—
|
132,051
|
Prepaid
expenses and other assets
|
666,501
|
565,181
|
Total
current assets
|
21,959,449
|
21,257,828
|
|
|
|
Property
and equipment, net
|
12,270,410
|
11,799,061
|
Operating
lease right-of-use assets
|
1,502,488
|
1,220,430
|
Intangible
assets, net
|
6,426,694
|
6,707,964
|
Goodwill
|
5,854,905
|
5,854,905
|
Deferred
tax assets, net
|
659,000
|
659,000
|
Other
assets
|
27,737
|
75,730
|
Total
assets
|
$48,700,683
|
$47,574,918
|
Liabilities and Stockholders’ Equity
|
|
|
Current
liabilities:
|
|
|
Accounts
payable
|
$2,337,477
|
$2,558,638
|
Accrued
liabilities
|
1,161,796
|
992,221
|
Accrued
payroll and benefits
|
1,976,053
|
1,827,740
|
Operating
lease liabilities, current
|
814,307
|
765,422
|
Loans
payable, current portion
|
881,350
|
981,350
|
Finance
lease obligation, current portion
|
284,008
|
278,040
|
Total
current liabilities
|
7,454,991
|
7,403,411
|
|
|
|
Finance
lease obligation, less current portion
|
205,966
|
279,435
|
Operating
lease liabilities, noncurrent
|
1,075,781
|
887,766
|
Loans
payable, less current portion
|
4,296,670
|
4,437,365
|
Total
liabilities
|
13,033,408
|
13,007,977
|
|
|
|
Commitments
and Contingencies
|
|
|
|
|
|
Stockholders’
equity:
|
|
|
Preferred
stock: Series D, $.01 par value, voting;
|
|
|
500,000
shares authorized; none issued and outstanding
|
—
|
—
|
Common
stock: Class A, $.01 par value, voting;
|
|
|
44,500,000
shares authorized; 26,102,831 and 25,891,885
|
|
|
shares
issued and outstanding
|
261,028
|
258,919
|
Additional
paid-in capital
|
230,905,905
|
230,634,056
|
Accumulated
other comprehensive income
|
1,465,200
|
735,892
|
Accumulated
deficit
|
(196,964,858)
|
(197,061,926)
|
Total
stockholders’ equity
|
35,667,275
|
34,566,941
|
Total
liabilities and stockholders’ equity
|
$48,700,683
|
$47,574,918
|
The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.
4
LIGHTPATH TECHNOLOGIES, INC.
Condensed Consolidated Statements of
Comprehensive Income (Loss)
(unaudited)
|
Three
Months Ended
|
|
|
September
30,
|
|
|
2020
|
2019
|
Revenue,
net
|
$9,508,972
|
$7,551,930
|
Cost
of sales
|
5,658,780
|
5,161,112
|
Gross
margin
|
3,850,192
|
2,390,818
|
Operating
expenses:
|
|
|
Selling,
general and administrative
|
2,440,477
|
2,341,778
|
New
product development
|
450,497
|
428,411
|
Amortization
of intangibles
|
281,271
|
283,521
|
Gain
on disposal of property and equipment
|
(45)
|
(50,000)
|
Total
operating expenses
|
3,172,200
|
3,003,710
|
Operating
income (loss)
|
677,992
|
(612,892)
|
Other
income (expense):
|
|
|
Interest
expense, net
|
(58,549)
|
(98,541)
|
Other
income (expense), net
|
(87,735)
|
(515,406)
|
Total
other income (expense), net
|
(146,284)
|
(613,947)
|
Income
(loss) before income taxes
|
531,708
|
(1,226,839)
|
Income
tax provision
|
434,640
|
148,318
|
Net
income (loss)
|
$97,068
|
$(1,375,157)
|
Foreign
currency translation adjustment
|
729,308
|
53,766
|
Comprehensive
income (loss)
|
$826,376
|
$(1,321,391)
|
Earnings
(loss) per common share (basic)
|
$0.00
|
$(0.05)
|
Number
of shares used in per share calculation (basic)
|
25,982,260
|
25,826,771
|
Earnings
(loss) per common share (diluted)
|
$0.00
|
$(0.05)
|
Number
of shares used in per share calculation (diluted)
|
28,432,275
|
25,826,771
|
The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.
5
LIGHTPATH TECHNOLOGIES, INC.
Condensed Consolidated Statements
of Changes in Stockholders' Equity
(unaudited)
|
Class A Common Stock Shares
|
Amount
|
Additional
Paid-in Capital
|
Accumulated
Other Comphrehensive Income
|
Accumulated Deficit
|
Total
Stockholders’ Equity
|
Balances at June 30, 2020
|
25,891,885
|
$258,919
|
$230,634,056
|
$735,892
|
$(197,061,926)
|
$34,566,941
|
Issuance
of common stock for:
|
|
|
|
|
|
|
Employee
Stock Purchase Plan
|
3,306
|
33
|
10,976
|
|
—
|
11,009
|
Exercise
of stock options, net
|
207,640
|
2,076
|
124,024
|
|
—
|
126,100
|
Stock-based
compensation on stock options & RSUs
|
—
|
—
|
136,849
|
—
|
—
|
136,849
|
Foreign
currency translation adjustment
|
—
|
—
|
—
|
729,308
|
—
|
729,308
|
Net
income
|
—
|
—
|
—
|
—
|
97,068
|
97,068
|
Balances at September 30, 2020
|
26,102,831
|
$261,028
|
$230,905,905
|
$1,465,200
|
$(196,964,858)
|
$35,667,275
|
|
|
|
|
|
|
|
Balances at June 30, 2019
|
25,813,895
|
$258,139
|
$230,321,324
|
$808,518
|
$(197,928,855)
|
$33,459,126
|
Issuance
of common stock for:
|
|
|
|
|
|
|
Employee
Stock Purchase Plan
|
13,370
|
134
|
12,033
|
—
|
—
|
12,167
|
Exercise
of RSUs, net
|
4,394
|
44
|
(44)
|
—
|
—
|
—
|
Stock-based
compensation on stock options & RSUs
|
—
|
—
|
98,459
|
—
|
—
|
98,459
|
Foreign
currency translation adjustment
|
—
|
—
|
—
|
53,766
|
—
|
53,766
|
Net
loss
|
—
|
—
|
—
|
—
|
(1,375,157)
|
(1,375,157)
|
Balances at September 30, 2019
|
25,831,659
|
$258,317
|
$230,431,772
|
$862,284
|
$(199,304,012)
|
$32,248,361
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.
6
|
Three
Months Ended September 30,
|
|
|
2020
|
2019
|
Cash
flows from operating activities:
|
|
|
Net
income (loss)
|
$97,068
|
$(1,375,157)
|
Adjustments
to reconcile net income (loss) to net cash provided by operating
activities:
|
|
|
Depreciation
and amortization
|
826,308
|
892,072
|
Interest
from amortization of debt costs
|
4,643
|
4,643
|
Gain
on disposal of property and equipment
|
(45)
|
(50,000)
|
Stock-based
compensation on stock options & RSUs, net
|
136,849
|
98,459
|
Change
in operating lease liabilities
|
(45,158)
|
(24,844)
|
Inventory
write-offs to allowance
|
112,282
|
—
|
Changes
in operating assets and liabilities:
|
|
|
Trade
accounts receivable
|
(70,201)
|
682,975
|
Other
receivables
|
132,051
|
353,695
|
Inventories
|
(775,234)
|
(332,161)
|
Prepaid
expenses and other assets
|
147,148
|
190,940
|
Accounts
payable and accrued liabilities
|
96,727
|
9,443
|
Net
cash provided by operating activities
|
662,438
|
450,065
|
|
|
|
Cash
flows from investing activities:
|
|
|
Purchase
of property and equipment
|
(1,216,817)
|
(256,573)
|
Proceeds
from sale of equipment
|
—
|
50,000
|
Net
cash used in investing activities
|
(1,216,817)
|
(206,573)
|
|
|
|
Cash
flows from financing activities:
|
|
|
Proceeds
from exercise of stock options
|
126,100
|
—
|
Proceeds
from sale of common stock from Employee Stock Purchase
Plan
|
11,009
|
12,167
|
Payments
on loan payable
|
(245,338)
|
(145,338)
|
Repayment
of finance lease obligations
|
(67,501)
|
(103,618)
|
Net
cash used in financing activities
|
(175,730)
|
(236,789)
|
Effect
of exchange rate on cash and cash equivalents
|
729,308
|
53,766
|
Change
in cash and cash equivalents and restricted cash
|
(801)
|
60,469
|
Cash
and cash equivalents, beginning of period
|
5,387,388
|
4,604,701
|
Cash
and cash equivalents, end of period
|
$5,386,587
|
$4,665,170
|
|
|
|
Supplemental
disclosure of cash flow information:
|
|
|
Interest
paid in cash
|
$54,089
|
$95,870
|
Income
taxes paid
|
$241,293
|
$57,660
|
The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.
7
LIGHTPATH TECHNOLOGIES, INC.
Notes to Unaudited Condensed
Consolidated Financial Statements
1.
Basis
of Presentation
References
in this document to “the Company,”
“LightPath,” “we,” “us,” or
“our” are intended to mean LightPath Technologies,
Inc., individually, or as the context requires, collectively with
its subsidiaries on a consolidated basis.
The
accompanying unaudited Condensed Consolidated Financial Statements
have been prepared in accordance with the requirements of Article 8
of Regulation S-X promulgated under the Exchange Act and,
therefore, do not include all information and footnotes necessary
for a fair presentation of financial position, results of
operations, and cash flows in conformity with accounting principles
generally accepted in the United States of America. These unaudited
Condensed Consolidated Financial Statements should be read in
conjunction with our Consolidated Financial Statements and related
notes, included in our Annual Report on Form 10-K for the fiscal
year ended June 30, 2020, filed with the Securities and Exchange
Commission (the “SEC”). Unless otherwise stated,
references to particular years or quarters refer to our fiscal
years ended June 30 and the associated quarters of those fiscal
years.
These
Condensed Consolidated Financial Statements are unaudited, but
include all adjustments, including normal recurring adjustments,
which, in the opinion of management, are necessary to present
fairly our financial position, results of operations and cash flows
for the interim periods presented. The Consolidated Balance Sheet
as of June 30, 2020 has been derived from the audited financial
statements at that date but does not include all of the information
and notes required by generally accepted accounting principles for
complete financial statements. Results of operations for interim
periods are not necessarily indicative of the results that may be
expected for the year as a whole. The unaudited Condensed
Consolidated Financial Statements include the accounts of the
Company and its wholly-owned subsidiaries. All significant
intercompany balances and transactions have been eliminated in
consolidation.
2.
Significant Accounting Policies
Our significant accounting policies are provided in Note 2,
Summary of
Significant Accounting Policies, in the Consolidated Financial Statements in our
Annual Report on Form 10-K for the fiscal year ended June 30,
2020.
Use of Estimates
Management makes estimates and assumptions during the preparation
of our unaudited Condensed Consolidated Financial Statements that
affect amounts reported in the unaudited Condensed Consolidated
Financial Statements and accompanying notes. Such estimates and
assumptions could change in the future as more information becomes
available, which, in turn, could impact the amounts reported and
disclosed herein.
Recently Adopted Accounting Standards
There have been no material changes to our significant accounting
policies during the three months ended September 30, 2020, from
those disclosed in our Annual Report on Form 10-K for the fiscal
year ended June 30, 2020.
3.
Revenue
Product Revenue
We are a manufacturer of optical components and higher-level
assemblies, including precision molded glass aspheric optics,
molded and diamond-turned infrared optical components, and other
optical materials used to produce products that manipulate light.
We design, develop, manufacture, and distribute optical components
and assemblies utilizing advanced optical manufacturing processes.
We also perform research and development for optical solutions for
a wide range of optics markets. Revenue is derived primarily from
the sale of optical components and assemblies.
Revenue Recognition
Revenue is generally recognized upon transfer of control, including
the risks and rewards of ownership, of promised products or
services to customers in an amount that reflects the consideration
we expect to receive in exchange for those products or services. We
generally bear all costs, risk of loss, or damage and retain title
to the goods up to the point of transfer of control of products to
customers. Shipping and handling costs are included in the cost of
goods sold. We present revenue net of sales taxes and any similar
assessments.
Customary payment terms are granted to customers, based on credit
evaluations. We currently do not have any contracts where revenue
is recognized, but the customer payment is contingent on a future
event. We record deferred revenue when cash payments are received
or due in advance of our performance. Deferred revenue was
immaterial as of June 30, 2020 and September 30, 2020.
Nature of Products
Revenue from the sale of optical components and assemblies is
recognized upon transfer of control, including the risks and
rewards of ownership, to the customer. The performance obligations
for the sale of optical components and assemblies are satisfied at
a point in time. Product development agreements are generally short
term in nature, with revenue recognized upon satisfaction of the
performance obligation, and transfer of control of the agreed-upon
deliverable. We have organized our products in three groups:
precision molded optics (“PMO”), infrared, and
specialty products. Revenues from product development agreements
are included in specialty products. Revenue by product group for
the three months ended September 30, 2020 and 2019 was as
follows:
8
|
Three
Months Ended September 30,
|
|
|
2020
|
2019
|
PMO
|
$4,293,603
|
$3,184,458
|
Infrared
Products
|
4,724,504
|
3,959,625
|
Specialty
Products
|
490,865
|
407,847
|
Total
revenue
|
$9,508,972
|
$7,551,930
|
4.
Inventories
The
components of inventories include the following:
|
September
30, 2020
|
June 30,
2020
|
Raw
materials
|
$4,111,137
|
$3,876,955
|
Work
in process
|
3,320,842
|
2,989,070
|
Finished
goods
|
3,192,137
|
3,134,800
|
Allowance
for obsolescence
|
(976,682)
|
(1,016,343)
|
|
$9,647,434
|
$8,984,482
|
The
value of tooling in raw materials, net of the related allowance for
obsolescence, was approximately $2.1 million and $2.3 million at
September 30, 2020 and June 30, 2020, respectively.
5.
Property and Equipment
Property
and equipment are summarized as follows:
|
Estimated
|
September
30,
|
June
30,
|
|
Lives
(Years)
|
2020
|
2020
|
Manufacturing
equipment
|
5 - 10
|
$19,875,155
|
$18,444,448
|
Computer
equipment and software
|
3 - 5
|
833,609
|
801,625
|
Furniture
and fixtures
|
5
|
340,036
|
321,418
|
Leasehold
improvements
|
5 - 7
|
2,469,818
|
2,171,388
|
Construction
in progress
|
|
685,988
|
1,274,880
|
Total
property and equipment
|
|
24,204,606
|
23,013,759
|
Less
accumulated depreciation and amortization
|
|
(11,934,196)
|
(11,214,698)
|
Total
property and equipment, net
|
|
$12,270,410
|
$11,799,061
|
9
6. Goodwill and Intangible Assets
There were no changes in the net carrying value of goodwill during
the three months ended September 30, 2020.
Identifiable intangible assets were comprised of:
|
Useful
Lives (Years)
|
September
30, 2020
|
June
30, 2020
|
Customer
relationships
|
15
|
$3,590,000
|
$3,590,000
|
Trade
secrets
|
8
|
3,272,000
|
3,272,000
|
Trademarks
|
8
|
3,814,000
|
3,814,000
|
Total
intangible assets
|
|
10,676,000
|
10,676,000
|
Less
accumulated amortization
|
|
(4,249,306)
|
(3,968,036)
|
Total
intangible assets, net
|
|
$6,426,694
|
$6,707,964
|
Future
amortization of identifiable intangibles is as
follows:
Fiscal
year ending:
|
|
June
30, 2021 (remaining nine months)
|
$843,813
|
June
30, 2022
|
1,125,083
|
June
30, 2023
|
1,125,083
|
June
30, 2024
|
1,125,083
|
June
30, 2025 and later
|
2,207,632
|
|
$6,426,694
|
7. Accounts Payable
The
accounts payable balance as of September 30, 2020 and June 30, 2020
both include approximately $91,000 of earned but unpaid Board of
Directors’ fees.
8. Income Taxes
A
summary of our total income tax expense and effective income tax
rate for the three months ended September 30, 2020 and 2019 is as
follows:
|
Three
Months Ended September 30,
|
|
|
2020
|
2019
|
Income
(loss) before income taxes
|
$531,708
|
$(1,226,839)
|
Income
tax provision
|
$434,640
|
$148,318
|
Effective
income tax rate
|
82%
|
-12%
|
10
The
difference between our effective tax rates in the periods presented
above and the federal statutory rate is due to the mix of taxable
income and losses generated in our various tax jurisdictions, which
include the United States (the “U.S.”), the
People’s Republic of China, and the Republic of Latvia. For
the three months ended September 30, 2020 and 2019, income tax
expense was primarily related to income taxes from our operations
in China. Income tax expense for the three months ended September
30, 2020 also includes withholding taxes of $300,000 accrued on a
$3 million intercompany dividend declared in July 2020 by LightPath
Optical Instrumentation (Zhenjiang) Co., Ltd.
(“LPOIZ”), which dividend will be paid to us, as its
parent company.
We record net deferred tax
assets to the extent we believe it is more likely than not that
some portion or all of these assets will be realized. The ultimate
realization of deferred tax assets is dependent upon the generation
of future taxable income during the periods in which those
temporary differences become deductible. We consider the scheduled
reversal of deferred tax liabilities, projected future taxable
income, and tax planning strategies in making this assessment. As
of September 30, 2020 and June 30, 2020, we have provided for a
valuation allowance against our net deferred tax assets to reduce
the net deferred tax assets to the amount we estimate is
more-likely-than-not to be realized. Our net deferred tax asset
consists primarily of U.S. net operating loss (“NOL”)
carryforward benefits, and federal and state tax credits with
indefinite carryover periods.
U.S. Federal and State Income Taxes
Our
U.S. federal and state statutory income tax rate is estimated to be
25.5%. Based on our current assessment of the valuation allowance
position on our net deferred tax assets, no additional tax benefit
is expected to be recorded on pre-tax losses generated in the
U.S.
Income Tax Law of the People’s Republic of China
Our Chinese subsidiaries, LightPath Optical Instrumentation
(Shanghai) Co., Ltd. (“LPOI”) and LightPath Optical
Instrumentation (Zhenjiang) Co., Ltd. (“LPOIZ”), are
governed by the Income Tax Law of the People’s Republic of
China. As of September 30, 2020, LPOI and LPOIZ were subject to
statutory income tax rates of 25% and 15%,
respectively.
In July 2020, we declared an intercompany dividend of $3 million
from LPOIZ, payable to us as its parent company. Accordingly, we
accrued Chinese withholding taxes of $300,000 associated with the
dividend. LPOIZ paid to us $900,000, after the withholding of
$100,000 in taxes, during the quarter ended September 30, 2020. The
remaining $200,000 of withholding taxes are included in accrued
liabilities in the accompanying unaudited Condensed Consolidated
Balance Sheet as of September 30, 2020. Other than these
withholding taxes, this intercompany dividend has no impact on our
unaudited Condensed Consolidated Financial Statements.
Historically, the Company considered unremitted earnings held by
its foreign subsidiaries to be permanently reinvested. However,
during fiscal 2020, the Company began declaring intercompany
dividends to remit a portion of the historical earnings of its
foreign subsidiaries to the U.S. parent company. It is still the
Company’s intent to reinvest a significant portion of the
more recent earnings generated by its foreign subsidiaries, however
the Company also plans to repatriate a portion of the historical
earnings of its subsidiaries. Based on its previous intent, the
Company had not historically provided for future Chinese
withholding taxes on the related earnings. However, during fiscal
2020 the Company began to accrue for these taxes on the portion of
historical earnings that it intends to repatriate.
Law of Corporate Income Tax of Latvia
Our Latvian subsidiary, ISP Optics Latvia, SIA (“ISP
Latvia”), is governed by the Law of Corporate Income Tax of
Latvia. Effective January 1, 2018, the Republic of Latvia enacted
tax reform with the following key provisions: (i) corporations are
no longer subject to income tax, but are instead subject to a
distribution tax on distributed profits (or deemed distributions,
as defined) and (ii) the rate of tax was changed to 20%; however,
distribution amounts are first divided by 0.8 to arrive at the
profit before tax amount, resulting in an effective tax rate of
25%. As a transitional measure, distributions of earnings prior to
January 1, 2018 are not subject to tax if declared prior to
December 31, 2019. ISP Latvia has declared an intercompany dividend
to be paid to ISP, its U.S. parent company, for the full amount of
earnings accumulated prior to January 1, 2018. Distributions of
this dividend will be from earnings prior to January 1, 2018 and,
therefore, will not be subject to tax. We currently do not intend
to distribute any earnings generated after January 1, 2018. If, in
the future, we change such intention, we will accrue distribution
taxes, if any, as profits are generated.
9. Stock-Based Compensation
Our directors, officers, and key employees are granted stock-based
compensation through our Amended and Restated Omnibus Incentive
Plan, as amended (the “Omnibus Plan”), through October
2018 and after that date, the 2018 Stock and Incentive Compensation
Plan (the “SICP”), including incentive stock options,
non-qualified stock options, and restricted stock unit
(“RSU”) awards. The stock-based compensation expense is
based primarily on the fair value of the award as of the grant
date, and is recognized as an expense over the requisite service
period.
11
The following table shows total stock-based compensation expense
for the three months ended September 30, 2020 and 2019 included in
the accompanying unaudited Condensed Consolidated Statements of
Comprehensive Income:
|
Three
Months Ended September 30,
|
|
|
2020
|
2019
|
|
|
|
Stock
options
|
$15,220
|
$3,495
|
RSUs
|
121,629
|
94,964
|
Total
|
$136,849
|
$98,459
|
|
|
|
The amounts above were included in:
|
|
|
Selling,
general & administrative
|
$136,849
|
$98,459
|
Cost
of sales
|
-
|
-
|
New
product development
|
-
|
-
|
|
$136,849
|
$98,459
|
Grant Date Fair Values and Underlying Assumptions; Contractual
Terms
We estimate the fair value of each stock option as of the date of
grant, using the Black-Scholes-Merton pricing model. The fair value
of 2014 ESPP shares is the amount of the discount the employee
obtains at the date of the purchase transaction.
Most stock options granted vest ratably over two to four years and
are generally exercisable for ten years. The assumed forfeiture
rates used in calculating the fair value of RSU grants was 0%, and
the assumed forfeiture rates used in calculating the fair value of
options for performance and service conditions were 20% for each of
the three months ended September 30, 2020 and 2019. The volatility
rate and expected term are based on seven-year historical trends in
Class A common stock closing prices and actual forfeitures. The
interest rate used is the U.S. Treasury interest rate for constant
maturities.
No stock options were granted in the three-month periods ended
September 30, 2020 and 2019.
Information Regarding Current Share-Based Compensation
Awards
A summary of the activity for share-based compensation awards in
the three months ended September 30, 2020 is presented
below:
|
Stock
Options
|
Restricted
Stock Units (RSUs)
|
|||
|
Shares
|
Weighted-Average
Exercise
Price
|
Weighted-Average
Remaining
Contract
|
Shares
|
Weighted-Average
Remaining
Contract
|
June 30, 2020
|
942,575
|
$1.65
|
6.5
|
2,328,303
|
0.9
|
|
|
|
|
|
|
Granted
|
—
|
$—
|
—
|
—
|
—
|
Exercised
|
(207,640)
|
$1.47
|
|
—
|
|
Cancelled/Forfeited
|
(373,058)
|
$1.71
|
|
—
|
|
September 30, 2020
|
361,877
|
$1.68
|
8.8
|
2,328,303
|
0.9
|
|
|
|
|
|
|
Awards
exercisable/
|
|
|
|
|
|
vested
as of
|
|
|
|
|
|
September 30, 2020
|
95,595
|
$1.65
|
7.4
|
1,658,777
|
—
|
|
|
|
|
|
|
Awards
unexercisable/
|
|
|
|
|
|
unvested
as of
|
|
|
|
|
|
September 30, 2020
|
266,282
|
$1.70
|
9.3
|
669,526
|
0.9
|
|
361,877
|
|
|
2,328,303
|
|
12
RSU awards vest immediately or from two to four years from the date
of grant.
As of September 30, 2020, there was approximately $649,000 of total
unrecognized compensation cost related to non-vested share-based
compensation arrangements (including stock options and RSUs)
granted. We expect to recognize the compensation cost as
follows:
Fiscal Year Ending:
|
Stock
Options
|
RSUs
|
Total
|
June
30, 2021 (remaining nine months)
|
$44,352
|
$181,425
|
$225,777
|
June
30, 2022
|
55,654
|
148,543
|
204,197
|
June
30, 2023
|
62,517
|
68,704
|
131,221
|
June
30, 2024
|
46,945
|
40,539
|
87,484
|
|
$209,468
|
$439,211
|
$648,679
|
10.
Earnings (Loss) Per Share
Basic earnings per share is computed by dividing net income or loss
by the weighted-average number of shares of Class A common stock
outstanding, during each period presented. Diluted earnings per
share is computed similarly to basic earnings per share, except
that it reflects the potential dilution that could occur if
dilutive securities or other obligations to issue shares of Class A
common stock were exercised or converted into shares of Class A
common stock. The computations for basic and diluted earnings per
share of Class A common stock are described in the following
table:
|
Three
Months Ended September 30,
|
|
|
2020
|
2019
|
|
|
|
Net
income (loss)
|
$97,068
|
$(1,375,157)
|
|
|
|
Weighted-average
common shares outstanding:
|
|
|
Basic number of shares
|
25,982,260
|
25,826,771
|
|
|
|
Effect
of dilutive securities:
|
|
|
Options
to purchase common stock
|
289,506
|
-
|
RSUs
|
2,160,509
|
-
|
Diluted number of shares
|
28,432,275
|
25,826,771
|
|
|
|
Earnings (loss) per common share:
|
|
|
Basic
|
$0.00
|
$(0.05)
|
Diluted
|
$0.00
|
$(0.05)
|
The following potential dilutive shares were not included in the
computation of diluted earnings per share of Class A common stock,
as their effects would be anti-dilutive:
|
Three
Months Ended September 30,
|
|
|
2020
|
2019
|
Options
to purchase common stock
|
517,502
|
979,925
|
RSUs
|
166,794
|
1,863,591
|
|
684,296
|
2,843,516
|
13
11.
Leases
The Company adopted ASC Topic 842 effective July 1, 2019. Our
leases primarily consist of operating leases related to our
facilities located in Orlando, Florida; Latvia; Shanghai, China;
and Zhenjiang, China, and finance leases related to certain
equipment located in Orlando, Florida. The operating leases for
facilities are non-cancelable operating leases, expiring through
2025. We include options to renew (or terminate) in our lease term,
and as part of our right-of-use ("ROU") assets and lease
liabilities, when it is reasonably certain that we will exercise
that option. We currently have obligations under four finance lease
agreements, entered into during fiscal years 2018 to 2019, with
terms ranging from three to five years. The leases are for computer
and manufacturing equipment.
Our operating lease ROU assets and the related lease liabilities
are initially measured at the present value of future lease
payments over the lease term. Two of our operating leases include
renewal options, which were not included in the measurement of the
operating lease ROU assets and related lease liabilities. As most
of our leases do not provide an implicit rate, we use our
collateralized incremental borrowing rate based on the information
available at the commencement date in determining the present value
of future payments. Currently, none of our leases include variable
lease payments that are dependent on an index or rate. We are
responsible for payment of certain real estate taxes, insurance and
other expenses on certain of our leases. These amounts are
generally considered to be variable and are not included in the
measurement of the ROU asset and lease liability. We generally
account for non-lease components, such as maintenance, separately
from lease components. Our lease agreements do not contain any
material residual value guarantees or material restricted
covenants. Leases with a term of 12 months or less are not recorded
on the balance sheet; we recognize lease expense for these leases
on a straight-line basis over the lease term.
We received tenant improvement allowances for each of our two
leases with respect to our facility located in Orlando, Florida
(the “Orlando Facility”). These allowances were used to
construct improvements and are included in leasehold improvements
and operating lease liabilities. The balances are being amortized
over the corresponding lease terms.
The components of lease expense were as follows:
|
Three
Months Ended September 30,
|
|
|
2020
|
2019
|
Operating
lease cost
|
$166,974
|
$164,871
|
Finance
lease cost:
|
|
|
Depreciation
of lease assets
|
65,869
|
86,063
|
Interest
on lease liabilities
|
12,824
|
22,532
|
Total
finance lease cost
|
78,693
|
108,595
|
Total
lease cost
|
$245,667
|
$273,466
|
Supplemental balance sheet information related to leases was as
follows:
|
Classification
|
September
30, 2020
|
June 30,
2020
|
Assets:
|
|
|
|
Operating
lease assets
|
Operating
lease assets
|
$1,502,488
|
$1,220,430
|
Finance
lease assets
|
Property and equipment, net(1)
|
619,165
|
666,519
|
Total
lease assets
|
|
$2,121,653
|
$1,886,949
|
|
|
|
|
Liabilities:
|
|
|
|
Current:
|
|
|
|
Operating
leases
|
Operating
lease liabilities, current
|
$814,307
|
$765,422
|
Short-term
leases
|
Accrued liabilities(2)
|
-
|
97,665
|
Finance
leases
|
Finance
lease liabilities, current
|
284,005
|
278,040
|
|
|
|
|
Noncurrent:
|
|
|
|
Operating
leases
|
Operating
lease liabilities, less current portion
|
1,075,781
|
887,766
|
Finance
leases
|
Finance
lease liabilities, less current portion
|
205,966
|
279,435
|
Total
lease liabilities
|
|
$2,380,059
|
$2,308,328
|
(1)
Finance
lease assets were recorded net of accumulated depreciation of
approximately $1.1 million as of September 30, 2020, and $1.0
million as of June 30, 2020.
(2)
Represents
accrual related to the lease of a manufacturing and office facility
in Irvington, New York, which we ceased use of as of June 30, 2019
as the relocation of the operations formerly housed in this
facility was complete. All remaining lease payments were accrued as
of that date, through the lease expiration in August
2020.
14
Lease term and discount rate information related to leases was as
follows:
Lease Term and Discount Rate
|
September 30, 2020
|
Weighted
Average Remaining Lease Term (in years)
|
|
Operating
leases
|
2.9
|
Finance
leases
|
1.9
|
|
|
Weighted
Average Discount Rate
|
|
Operating
leases
|
4.6%
|
Finance
leases
|
7.9%
|
Supplemental cash flow information:
|
Three
Months Ended September 30,
|
|
|
2020
|
2019
|
Cash paid for amounts included in the measurement of lease
liabilities:
|
|
|
Operating
cash used for operating leases
|
$212,132
|
$189,715
|
Operating
cash used for finance leases
|
$12,824
|
$22,545
|
Financing
cash used for finance leases
|
$67,501
|
$103,618
|
Future maturities of lease liabilities were as follows as of
September 30, 2020:
Fiscal year ending:
|
Finance
Leases
|
Operating
Leases
|
June
30, 2021 (remaining nine months)
|
$240,972
|
$653,026
|
June
30, 2022
|
231,783
|
822,780
|
June
30, 2023
|
59,647
|
237,341
|
June
30, 2024
|
11,811
|
117,852
|
June
30, 2025
|
—
|
117,852
|
Total
future minimum payments
|
544,213
|
1,948,851
|
Less
imputed interest
|
(54,242)
|
(58,763)
|
Present
value of lease liabilities
|
$489,971
|
$1,890,088
|
12.
Loans Payable
During the three months ended September 30, 2019, loans payable
consisted of the BankUnited Term Loan (as defined below) payable to
BankUnited N.A. (“BankUnited”). On February 26, 2019,
we entered into a Loan Agreement (the “Loan Agreement”)
with BankUnited for (i) a revolving line of credit up to maximum
amount of $2,000,000 (the “BankUnited Revolving Line”),
(ii) a term loan in the amount of up to $5,813,500
(“BankUnited Term Loan”), and (iii) a non-revolving
guidance line of credit up to a maximum amount of $10,000,000 (the
“Guidance Line” and, together with the BankUnited
Revolving Line and BankUnited Term Loan, the “BankUnited
Loans”). Each of the BankUnited Loans is evidenced by a
promissory note in favor of BankUnited (the “BankUnited
Notes”). Simultaneously with the execution of the Loan
Agreement, we used the proceeds from the BankUnited Term Loan to
pay in full, all outstanding amounts owed to Avidbank Corporate
Finance, a division of Avidbank (“Avidbank”) pursuant
to an acquisition term loan. For additional information related to
the Avidbank loans, please see Note 17, Loans
Payable, to our audited
Consolidated Financial Statements in our Annual Report on Form 10-K
for the year ended June 30, 2020.
On May 6, 2019, we entered into that certain First Amendment to
Loan Agreement, effective February 26, 2019, with BankUnited (the
“Amendment” and, together with the Loan Agreement, the
“Amended Loan Agreement”). The Amendment amended the
definition of the fixed charge coverage ratio to more accurately
reflect the parties’ understandings at the time the Loan
Agreement was executed.
15
BankUnited Revolving Line
Pursuant to the Amended Loan Agreement, BankUnited will make loan
advances under the BankUnited Revolving Line to us up to a maximum
aggregate principal amount outstanding not to exceed $2,000,000,
which proceeds will be used for working capital and general
corporate purposes. Amounts borrowed under the BankUnited Revolving
Line may be repaid and re-borrowed at any time prior to February
26, 2022, at which time all amounts will be immediately due and
payable. The advances under the BankUnited Revolving Line bear
interest, on the outstanding daily balance, at a per annum rate
equal to 2.75% above the 30-day LIBOR. Interest payments are due
and payable, in arrears, on the first day of each month. As of
September 30, 2020, the applicable interest rate was
2.91%.
BankUnited Term Loan
Pursuant to the Amended Loan Agreement, BankUnited advanced us
$5,813,500 to satisfy in full the amounts owed to Avidbank,
including the outstanding principal amount and all accrued interest
under the acquisition term loan and to pay the fees and expenses
incurred in connection with closing of the BankUnited Loans. The
BankUnited Term Loan is for a 5-year term, but co-terminus with the
BankUnited Revolving Line should the BankUnited Revolving Line not
be renewed beyond February 26, 2022. Management expects the
BankUnited Revolving Line to be renewed. The BankUnited Term Loan
bears interest at a per annum rate equal to 2.75% above the 30-day
LIBOR. Equal monthly principal payments of $48,445.83, plus accrued
interest, are due and payable, in arrears, on the first day of each
month during the term. Upon maturity, all principal and interest
shall be immediately due and payable. As of September 30, 2020, the
applicable interest rate was 2.91%.
Guidance Line
Pursuant to the Amended Loan Agreement, BankUnited, in its sole
discretion, may make loan advances to us under the Guidance Line up
to a maximum aggregate principal amount outstanding not to exceed
$10,000,000, which proceeds will be used for capital expenditures
and approved business acquisitions. Such advances must be in
minimum amounts of $1,000,000 for acquisitions and $500,000 for
capital expenditures, and will be limited to 80% of cost or as
otherwise determined by BankUnited. Amounts borrowed under the
Guidance Line may not re-borrowed. The advances under the Guidance
Line bear interest, on the outstanding daily balance, at a per
annum rate equal to 2.75% above the 30-day LIBOR. Interest payments
are due and payable, in arrears, on the first day of each month. On
each anniversary of the Amended Loan Agreement, monthly principal
payments become payable, amortized based on a ten-year term. There
were no borrowings under the Guidance Line as of September 30,
2020.
Security and Guarantees
Our obligations under the Amended Loan Agreement are collateralized
by a first priority security interest (subject to permitted liens)
in all of our assets and the assets of our U.S. subsidiaries,
GelTech, Inc. (“GelTech”), and ISP, pursuant to a
Security Agreement granted by GelTech, ISP, and us in favor of
BankUnited. Our equity interests in, and the assets of, our foreign
subsidiaries are excluded from the security interest. In addition,
all of our subsidiaries have guaranteed our obligations under the
Amended Loan Agreement and related documents, pursuant to Guaranty
Agreements executed by us and our subsidiaries in favor of
BankUnited.
General Terms
The Amended Loan Agreement contains customary covenants, including,
but not limited to: (i) limitations on the disposition of property;
(ii) limitations on changing our business or permitting a change in
control; (iii) limitations on additional indebtedness or
encumbrances; (iv) restrictions on distributions; and (v)
limitations on certain investments. The Amended Loan Agreement also
contains certain financial covenants, including obligations to
maintain a fixed charge coverage ratio of 1.25 to 1.00 and a total
leverage ratio of 4.00 to 1.00. As of September 30, 2020, the
Company was in compliance with all required covenants.
We may prepay any or all of the BankUnited Loans in whole or in
part at any time, without penalty or premium. Late payments are
subject to a late fee equal to five percent (5%) of the unpaid
amount. Amounts outstanding during an event of default accrue
interest at a rate of five percent (5%) above the 30-day LIBOR
applicable immediately prior to the occurrence of the event of
default. The Amended Loan Agreement contains other customary
provisions with respect to events of default, expense
reimbursement, and confidentiality.
Financing costs incurred were recorded as a discount on debt and
will be amortized over the term. Amortization of approximately
$4,600 is included in interest expense for both the three months
ended September 30, 2020 and 2019.
16
Future maturities of loans payable are as follows:
|
BankUnited Term Loan
|
BankUnited Revolver
|
Unamortized Debt Costs
|
Total
|
Fiscal year ending:
|
|
|
|
|
June
30, 2021 (remaining nine months)
|
$436,012
|
$300,000
|
$(13,929)
|
$722,083
|
June
30, 2022
|
581,350
|
-
|
(18,572)
|
562,778
|
June
30, 2023
|
581,350
|
-
|
(18,572)
|
562,778
|
June
30, 2024
|
3,342,762
|
-
|
(12,381)
|
3,330,381
|
Total
payments
|
$4,941,474
|
$300,000
|
$(63,454)
|
5,178,020
|
Less
current portion
|
|
|
|
(881,350)
|
Non-current
portion
|
|
|
|
$4,296,670
|
13.
Foreign
Operations
Assets and liabilities denominated in non-U.S. currencies are
translated at rates of exchange prevailing on the balance sheet
date, and revenues and expenses are translated at average rates of
exchange for the period. Gains or losses on the translation of the
financial statements of a non-U.S. operation, where the functional
currency is other than the U.S. dollar, are reflected as a separate
component of equity, which was a cumulative gain of approximately
$1.5 million and $862,000 as of September 30, 2020 and 2019,
respectively. During the three months ended September 30, 2020 and
2019, we also recognized net foreign currency transaction losses of
approximately $98,000 and $497,000, respectively, included in the
unaudited Condensed Consolidated Statements of Comprehensive Income
(Loss) in the line item entitled “Other income (expense),
net.”
Our
cash and cash equivalents totaled $5.4 million at September 30,
2020. Of this amount, greater than 50% was held by our foreign
subsidiaries in China and Latvia. These foreign funds were
generated in China and Latvia as a result of foreign earnings. With
respect to the funds generated by our foreign subsidiaries in
China, the retained earnings of the respective subsidiary must
equal at least 50% of its registered capital before any funds can
be repatriated through dividends. As of December 31, 2019, the end
of the most recent statutory tax year, LPOIZ had approximately $4.8
million available for repatriation and LPOI did not have any
earnings available for repatriation.
Assets
and net assets in foreign countries are as follows:
|
China
|
Latvia
|
||
|
September
30, 2020
|
June
30, 2020
|
September
30, 2020
|
June
30, 2020
|
Assets
|
$19.4 million
|
$19.0 million
|
$10.2 million
|
$9.8 million
|
Net assets
|
$16.6 million
|
$16.2 million
|
$8.8 million
|
$8.2 million
|
14.
Contingencies
Legal
The Company from time to time is involved in various legal actions
arising in the normal course of business. Management, after
reviewing with legal counsel all of these actions and proceedings,
believes that the aggregate losses, if any, will not have a
material adverse effect on the Company’s financial position
or results of operations.
COVID-19
The Company’s business, results of operations financial
condition, cash flows, and the stock price of its Class A common
stock can be adversely affected by pandemics, epidemics, or other
public health emergencies, such as the recent outbreak of the novel
coronavirus (“COVID-19”), which has spread from China
to many other countries across the world, including the United
States.
To date, the Company has not experienced any significant direct
negative impact of COVID-19 to its business. However, the COVID-19
pandemic continues to impact economic conditions, which could
impact the short-term and long-term demand from customers and,
therefore, has the potential to negatively impact the
Company’s results of operations, cash flows, and financial
position in the future. Management is actively monitoring this
situation and any impact on our financial condition, liquidity, and
results of operations. However, given the daily evolution of the
COVID-19 pandemic and the global responses to curb its spread, we
are not presently able to estimate the effects of the COVID-19
pandemic on our future results of operations, financial, or
liquidity for the remainder of fiscal year 2021 or
beyond.
17
Item 2. Management’s Discussion and
Analysis of Financial Condition and Results of
Operations
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations is designed to provide a reader of the financial
statements with a narrative report on our financial condition,
results of operations, and liquidity. This discussion and analysis
should be read in conjunction with the attached unaudited Condensed
Consolidated Financial Statements and notes thereto and our Annual
Report on Form 10-K for the year ended June 30, 2020, including the
audited Consolidated Financial Statements and notes thereto. The
following discussion contains forward-looking statements that
involve risks and uncertainties, such as statements of our plans,
objectives, expectations, and intentions. Our actual results could
differ materially from those discussed in the forward-looking
statements. Please also see the cautionary language at the
beginning of this Quarterly Report regarding forward-looking
statements.
The discussions of our results as presented in this Quarterly
Report include use of the non-GAAP term “gross margin,”
as well as other non-GAAP measures discussed in more detail under
the heading “Non-GAAP Financial Measures.” Gross margin
is determined by deducting the cost of sales from operating
revenue. Cost of sales includes manufacturing direct and indirect
labor, materials, services, fixed costs for rent, utilities and
depreciation, and variable overhead. Gross margin should not be
considered an alternative to operating income or net income, which
are determined in accordance with GAAP. We believe that gross
margin, although a non-GAAP financial measure, is useful and
meaningful to investors as a basis for making investment decisions.
It provides investors with information that demonstrates our cost
structure and provides funds for our total costs and expenses. We
use gross margin in measuring the performance of our business and
have historically analyzed and reported gross margin information
publicly. Other companies may calculate gross margin in a different
manner.
Potential Impact of COVID-19
In March 2020, the World Health Organization ("WHO") declared the
outbreak of COVID-19 as a pandemic based on the rapid increase in
global exposure. COVID-19 continues to spread throughout world,
including the United States. Throughout the COVID-19 pandemic, our
manufacturing facilities in China, Latvia, and the United States
have continued to operate as normal. Some of our United States- and
Latvia-based non-manufacturing employees are continuing to work
remotely, either on a full or partial basis. Where possible, we
have staggered shifts to reduce contact within shifts and between
different shifts, and have minimized interaction and physical
proximity between employees working within the same building. To
date, we have not seen any significant direct negative impact of
COVID-19 to our business. However, the COVID-19 pandemic continues
to impact economic conditions, which could impact the short-term
and long-term demand from our customers and, therefore, has the
potential to negatively impact our results of operations, cash
flows, and financial position in the future. In addition, we have
seen increased demand for thermal imaging assemblies for fever
detection applications in response to the pandemic. Management is
actively monitoring this situation and any impact on our financial
condition, liquidity, and results of operations. However, given the
daily evolution of the COVID-19 pandemic and the global responses
to curb its spread, we are not presently able to estimate the
effects of the COVID-19 pandemic on our future results of
operations, financial, or liquidity for the remainder of fiscal
year 2021 and, possibly, beyond.
Introduction
We were incorporated in Delaware in 1992 as the successor to
LightPath Technologies Limited Partnership, a New Mexico limited
partnership, formed in 1989, and its predecessor, Integrated Solar
Technologies Corporation, a New Mexico corporation, formed in 1985.
Today, LightPath is a global company with major facilities in the
United States, the People’s Republic of China, and the
Republic of Latvia.
Our capabilities include precision molded optics, thermal imaging
optics, custom designed optics and optical assemblies and
subsystems. These capabilities allow us to manufacture optical
components and higher-level assemblies, including precision molded
glass aspheric optics, molded and diamond-turned infrared aspheric
lenses and other optical materials used to produce products that
manipulate light. We design, develop, manufacture and distribute
optical components and assemblies utilizing advanced optical
manufacturing processes. We serve a wide and diverse number of
industries including defense and security, optical systems and
components, datacom/telecom, information technology, life sciences,
machine vision and production technology. Our products are
incorporated into a variety of applications by our broad and
diverse customer base. These applications include defense products,
medical devices, laser aided industrial tools, automotive safety
applications, barcode scanners, optical data storage, hybrid fiber
coax datacom, telecommunication optical networks, machine vision
and sensors, among others. All the products we produce enable
lasers and imaging devices to function more
effectively.
Subsidiaries
In November 2005, we formed LPOI, a wholly-owned subsidiary, located in
Jiading, People’s Republic of China. LPOI provides sales and
support functions. In December 2013, we formed LPOIZ, a
wholly-owned subsidiary located in the New City district, of the
Jiangsu province, of the People’s Republic of China.
LPOIZ’s 55,000 square foot manufacturing facility (the
“Zhenjiang Facility”) serves as our primary
manufacturing facility in China and provides a lower cost structure
for production of larger volumes of optical components and
assemblies.
18
In December 2016, we acquired ISP, and its wholly-owned subsidiary,
ISP Latvia. ISP is a vertically integrated manufacturer offering a
full range of infrared products from custom infrared optical
elements to catalog and high-performance lens assemblies.
Historically, ISP’s facility located in Irvington, New York
functioned as its global headquarters for operations, while also
providing manufacturing capabilities, optical coatings, and optical
and mechanical design, assembly, and testing. In June 2019, we
completed the relocation of this facility to our existing Orlando
Facility and our facility located in Riga, Latvia (the “Riga
Facility”). ISP Latvia is a manufacturer of high precision
optics and offers a full range of infrared products, including
catalog and custom infrared optics. ISP Latvia’s Riga
Facility functions as its manufacturing facility.
For additional information, please refer to our Annual Report on
Form 10-K for the year ended June 30, 2020.
Growth Strategy
During the last three months of fiscal 2020, our leadership worked
to develop and re-define our strategic direction. We are a
component company with deep roots in optics manufacturing
technology, known for our innovative products and solutions, which
technology we have leveraged over the years to focus on the
delivery of “best in class” and cost leading optical
components. Initially, we focused on standard glass PMO products,
and later, through the acquisition of ISP, as well as through
internal research and development, we began to shift our focus to
products specific to the infrared market.
As is typical with a company with origins in component
manufacturing, for years we focused on our products and technology,
and as a result, have become a leader in molded optical glass
components. We then leveraged that experience and know-how into
infrared optics. However, during the 30 years since we began
delivering our innovative molded optics, the uses of optical
technology have grown exponentially, and consequently, the optics
industry has evolved.
With the expansion of optical applications into many industries,
technologies, and products, our customers’ needs and
expectations have changed. Customers now often seek a partner that
can complement their capabilities and support their implementation
of optics and integration of photonics technologies into their
products. These partnerships are formed based on our offering of
complete optical solutions, to be integrated into the system,
rather than discrete optical components. We believe we are well
positioned to become the partner of choice for OEM customers
integrating optics into their products because of our optical
technologies expertise, design of optical systems, and
manufacturing of the individual components, as well as
assemblies.
To execute on this strategic direction, we have been focusing on
aligning the organization to this new strategic direction in terms
of structure, resources and processes. Additionally, we are focused
on identifying and developing any capabilities and infrastructure
we need to support the execution of this strategy. Further
information about our strategic direction can be found in our
recent Annual Report on Form 10-K for the fiscal year ended June
30, 2020.
Product Groups and Markets
Our business is organized in three product groups: PMO,
infrared products and specialty products. These product groups are
supported by our major product capabilities: molded optics, thermal
imaging optics, and custom designed optics. Beginning late in
fiscal 2019, we implemented a product management function by
designating a product manager for each of our major product
capabilities. This function has begun to facilitate choosing
investment priorities to help strategically align our competencies
with revenue opportunities in strategic industries. Over the
long-term, we believe this function will also help ensure
successful product life cycle management.
Our PMO product group consists of visible precision molded optics
with varying applications. Our infrared product group is comprised
of infrared optics, both molded and diamond-turned, and thermal
imaging assemblies. This product group also includes both
conventional and CNC ground and polished lenses. Between these two
product groups, we have the capability to manufacture lenses from
very small (with diameters of sub-millimeter) to over 300
millimeters, and with focal lengths from approximately 0.4mm to
over 2000mm. In addition, both product groups offer both catalog
and custom designed optics.
Our specialty product group is comprised of value-added products,
such as optical subsystems, assemblies, and collimators, and
non-recurring engineering (“NRE”) products, consisting
of those products we develop pursuant to product development
agreements that we enter into with customers. Typically, customers
approach us and request that we develop new products or
applications for our existing products to fit their particular
needs or specifications. The timing and extent of any such product
development is outside of our control.
19
We have also aligned our marketing efforts by our capabilities
(i.e., molded optics, thermal imaging optics, and custom
optics), and then by industry. We currently serve the following
major markets: defense and security, optical systems and
components, datacom/telecom, information technology, life sciences,
machine vision and production technology. Customers in each of
these markets may select the best optical technologies that suit
their needs from our entire suite of products, availing us to
cross-selling opportunities, particularly where we can leverage our
knowledge base against our expanding design library. Within our
product groups, we have various applications that serve our major
markets. For example, our infrared products can be used for gas
sensing devices, temperature sensing and fever detection,
spectrometers, night vision systems, advanced driver-assistance
systems (“ADAS”), thermal weapon gun sights, and
infrared counter measure systems, among others.
The photonics market drives our growth and is comprised of eight
application areas: information and communication technology,
display, lighting, photovoltaic, production technology, life
sciences, and measurement and automated vision. In 2018, the market
size for these applications at the system level was $556.4 billion.
LightPath has product applications in six of the eight application
areas, all except for displays and photovoltaic. According to the
latest Markets and Markets survey, published in 2019, these six
application areas had an estimated market value of $401 billion and
are growing at a 7% compound annual growth rate. Within the larger
overall markets, we believe there is a market of approximately $2.0
billion for our current products and capabilities. We continue to
believe our products will provide significant growth opportunities
over the next several years and, therefore, we will continue to
target specific applications in each of these major markets. In
addition to these major markets, a large percentage of our revenues
are derived from sales to unaffiliated companies that purchase our
products to fulfill their customers’ orders, as well as
unaffiliated companies that offer our products for sale in their
catalogs.
Our strategy is to capitalize on optics as an enabling technology
across many industries and markets, by leveraging our key
differentiators, including our deep design and manufacturing
expertise, our technology, and our established low-cost vertically
integrated manufacturing capabilities. In addition, we intend for
our product managers and sales force to work together to focus on
pursuing customer growth opportunities where our differential
advantages coincide with key customer needs.
Results of
Operations
Fiscal First Quarter: Three months ended September 30, 2020,
compared to three months ended September 30, 2019
Revenues:
Revenue for the first quarter of fiscal 2021 was approximately $9.5
million, an increase of approximately $2 million, or 26%, as
compared to $7.6 million in the same period of the prior fiscal
year. Revenue generated by infrared products was approximately $4.7
million in the first quarter of fiscal 2021, an increase of
approximately $765,000, or 19%, as compared to approximately $4.0
million in the same period of the prior fiscal year. The increase
in revenue is attributed to increases in sales to customers in the
commercial, industrial and defense markets. Revenue generated by
PMO products was approximately $4.3 million for the first quarter
of fiscal 2021, as compared to $3.2 million in the same period of
the prior fiscal year, an increase of approximately $1.1 million,
or 35%. The increase in revenue is attributed to an increase in
sales to customers in the telecommunications market, as well as the
commercial and defense markets. Revenue generated by our specialty
products was approximately $491,000 in the first quarter of fiscal
2021, an increase of approximately $83,000, or 20%, compared to
$408,000 in the same period of the prior fiscal year. This increase
is primarily related to increased sales of collimator assemblies to
customers in the industrial and commercial markets.
Cost of Sales and Gross Margin:
Gross margin in the first quarter of fiscal 2021 was approximately
$3.9 million, an increase of 61%, as compared to approximately $2.4
million in the same period of the prior fiscal year. Total cost of
sales was approximately $5.7 million for the first quarter of
fiscal 2021, compared to $5.2 million for the same period of the
prior fiscal year. The increases in gross margin and cost of sales
are primarily driven by the growth in revenue. Gross margin as a
percentage of revenue was 40% for the first quarter of fiscal 2021,
compared to 32% for the first quarter of fiscal 2020. The increase
in gross margin as a percentage of revenue is primarily due to the
increase in revenue and volumes across all of our product groups.
In addition, there were several factors that negatively impacted
the first quarter of fiscal 2020, such as increased tariffs, the
impacts of which have since been mitigated. We continue to improve
yields on our BD6 products, which contributed to higher costs and
lower margins during the first quarter of fiscal 2020. Volumes
continue to increase for our BD6-based infrared molded
products, and margins are expected to continue to improve as
these products mature. In addition, development efforts to
convert certain germanium-based diamond-turned infrared products to
BD6 material are ongoing, which is expected to further improve
infrared margins over time.
Selling, General and Administrative:
Selling, general and administrative (“SG&A”) costs
were approximately $2.4 million for the first quarter of fiscal
2021, an increase of approximately 4%, as compared to approximately
$2.3 million in the same quarter of the prior fiscal year. The
increase is due to an increase in personnel-related costs
associated with a moderate increase in headcount, as well as an
increase in outside consulting services for projects related to
operational improvements.
New Product Development:
New product development costs were approximately $450,000 in the
first quarter of fiscal 2021, an increase of approximately $22,000,
or 5%, as compared to the same period of the prior fiscal year.
This increase was primarily due to additional engineering support
to accomodate the demand for optical design. We anticipate that new
product development expenses will remain at similar levels for the
remainder of fiscal 2021; however, actual expenses will depend on
the demand for product development.
20
Other Income (Expense):
In the first quarter of fiscal 2021, interest expense was
approximately $59,000, compared to approximately $99,000 in the
same period of the prior fiscal year. The decrease in interest
expense is due to lower interest rates and an 11% reduction in
total debt from September 30, 2019 to September 30, 2020. We expect
that interest expense will remain near current levels for the
remainder of fiscal 2021.
Other expense, net, was approximately $88,000 in the first quarter
of fiscal 2021, compared to $515,000 in the same period of the
prior fiscal year, primarily resulting from net losses on foreign
exchange transactions. We execute all foreign sales from our U.S.
facilities and inter-company transactions in U.S. dollars,
partially mitigating the impact of foreign currency fluctuations.
Assets and liabilities denominated in non-United States currencies,
primarily the Chinese Yuan and Euro, are translated at rates of
exchange prevailing on the balance sheet date, and revenues and
expenses are translated at average rates of exchange for the year.
During the first quarter of fiscal 2021, we incurred a net foreign
currency transaction loss of approximately $98,000, compared to
$497,000 for the same period of the prior fiscal year.
Income Taxes:
During the first quarter of fiscal 2021, we recorded income tax
expense of approximately $435,000, compared to approximately
$148,000 for the same period of the prior fiscal year, primarily
related to income taxes from our operations in China. Income taxes
for the first quarter of fiscal 2021 also included Chinese
withholding taxes of $300,000 associated with the intercompany
dividend declared by LPOIZ during the first quarter. While this
repatriation transaction resulted in some additional Chinese
withholding taxes, LPOIZ currently qualifies for a reduced Chinese
income tax rate; therefore, the total income tax on those earnings
was still lower than it would have been using the normal income tax
rate. Please refer to Note 8, Income
Taxes, in the unaudited
Condensed Consolidated Financial Statements in this Quarterly
Report on Form 10-Q for additional information.
Net Income (Loss):
Net income for the first quarter of fiscal 2021 was approximately
$97,000, or $0.00 basic and diluted earnings per share, compared to
a net loss of $1.4 million, or $0.05 basic and diluted loss per
share, for the first quarter of fiscal 2020. The increase in net
income for the first quarter of fiscal 2021 is primarily
attributable to the increase in revenue, resulting in higher gross
margin, partially offset by moderate increases in SG&A and new
product development costs. These differences increased operating
income by approximately $1.3 million for the first quarter of
fiscal 2021, as compared to the same period of the prior fiscal
year. In addition, there was a favorable difference of
approximately $400,000 on foreign currency transaction losses,
partially offset by an unfavorable difference of approximately
$286,000 in the provision for income taxes.
Weighted-average common shares outstanding were 25,982,260 and
28,432,275, basic and diluted, respectively, in the first quarter
of fiscal 2021, compared to 25,826,771, for both basic and diluted,
in the first quarter of fiscal 2020. The increase in the
weighted-average basic common shares was due to the issuance of
shares of Class A common stock under the 2014 ESPP and upon the
exercises of stock options.
Liquidity and Capital
Resources
As of September 30, 2020, we had working capital of approximately
$14.5 million and total cash and cash equivalents of approximately
$5.4 million, of which, greater than 50% of our cash and cash
equivalents was held by our foreign subsidiaries.
Cash and cash equivalents held by our foreign subsidiaries in China
and Latvia were generated in-country as a result of foreign
earnings. Historically, we considered unremitted earnings held by
our foreign subsidiaries to be permanently reinvested. However,
during fiscal 2020, we began declaring intercompany dividends to
remit a portion of the earnings of our foreign subsidiaries to us,
as the U.S. parent company. It is still our intent to reinvest a
significant portion of earnings generated by our foreign
subsidiaries, however we also plan to repatriate a portion of their
earnings.
In China, before any funds can be repatriated, the retained
earnings of the legal entity must equal at least 50% of the
registered capital. During fiscal 2020, we repatriated
approximately $2 million from LPOIZ. Based on retained earnings as
of December 31, 2019, the end of the prior statutory tax year,
LPOIZ had an additional $4.8 million available and LPOI did not
have any earnings available for repatriation. Based on our previous
intent, we had not historically provided for future Chinese
withholding taxes on the related earnings. However, during fiscal
2020 we began to accrue for these taxes on the portion of earnings
that we intend to repatriate.
Loans payable consists of the BankUnited Term Loan pursuant to the
Amended Loan Agreement. The Amended Loan Agreement also provides
for a BankUnited Revolving Line and a Guidance Line. As of
September 30, 2020, the outstanding balance on the BankUnited Term
Loan was approximately $4.9 million, the outstanding balance on the
BankUnited Revolving Line was $300,000, and there were no
borrowings outstanding on the Guidance Line.
The Amended Loan Agreement includes certain customary covenants. As
of September 30, 2020, we were in compliance with all covenants.
For additional information, see Note 12, Loans
Payable, to the unaudited
Condensed Consolidated Financial Statements in this Quarterly
Report on Form 10-Q.
We generally rely on cash from operations and equity and debt
offerings, to the extent available, to satisfy our liquidity needs
and to maintain our ability to repay the BankUnited Term Loan.
There are a number of factors that could result in the need to
raise additional funds, including a decline in revenue or a lack of
anticipated sales growth, increased material costs, increased labor
costs, planned production efficiency improvements not being
realized, increases in property, casualty, benefit and liability
insurance premiums, and increases in other costs. We will also
continue efforts to keep costs under control as we seek renewed
sales growth. Our efforts are directed toward generating positive
cash flow and profitability. If these efforts are not successful,
we may need to raise additional capital. Should capital not be
available to us at reasonable terms, other actions may become
necessary in addition to cost control measures and continued
efforts to increase sales. These actions may include exploring
strategic options for the sale of the Company, the sale of certain
product lines, the creation of joint ventures or strategic
alliances under which we will pursue business opportunities, the
creation of licensing arrangements with respect to our technology,
or other alternatives.
21
Cash Flows – Financings:
Net cash used in financing activities was approximately $176,000 in
the first quarter of fiscal 2021, compared to approximately
$237,000 used in the same period of the prior fiscal year. Cash
used in financing activities for the first quarter of fiscal 2021
reflects approximately $313,000 in principal payments on our loans
and finance leases, net of approximately $137,000 in proceeds from
the exercise of stock options, and from the sale of Class A common
stock under the 2014 ESPP. Cash used in financing activities for
the first quarter of fiscal 2020 reflects approximately $249,000 in
principal payments on our loans and capital leases, net of
approximately $12,000 in proceeds from the sale of Class A common
stock under the 2014 ESPP.
Cash Flows – Operating:
Cash flow provided by operations was approximately $662,000 for the
first quarter of fiscal 2020, compared to approximately $450,000
for the same period of the prior fiscal year. The increase in cash flow from operations for the
first quarter of fiscal 2021 is primarily due to the increase in
net income, partially offset by an increase in inventory driven by
the growth in revenue and backlog. We anticipate continued
improvement in our cash flows provided by operations in future
years, based on our forecasted sales growth and anticipated margin
improvements, partially offset by marginal increases in sales and
marketing, and new product development
expenditures.
Cash Flows – Investing:
During the first quarter of fiscal 2021, we expended approximately
$1.2 million in investments in capital equipment, compared to
approximately $257,000 in the first quarter of fiscal 2020. The
majority of our capital expenditures during the first quarter of
fiscal 2021 were related to the continued expansion of our infrared
coating capacity as well as increasing our lens pressing and dicing
capacity to meet current and forecasted demand. Overall, we anticipate that the level of capital
expenditures during fiscal 2021 will be higher than in fiscal 2020,
however, the total amount expended will depend on opportunities and
circumstances.
Contractual Obligations and
Commitments
As of September 30, 2020, our principal commitments consisted of
obligations under operating and finance leases, and debt
agreements. No material changes occurred during the first quarter
of fiscal 2021 in our contractual cash obligations to repay debt or
to make payments under operating and finance leases, or in our
contingent liabilities as disclosed in our Annual Report on Form
10-K for the year ended June 30, 2020.
Off Balance Sheet
Arrangements
We do not engage in any activities involving variable interest
entities or off-balance sheet arrangements.
Critical Accounting Policies
and Estimates
There have been no material changes to our critical accounting
policies and estimates during the three months ended September 30,
2020 from those disclosed in Item 7. Management’s Discussion
and Analysis of Financial Condition and Results of Operations, of
our Annual Report on Form 10-K for the year ended June 30,
2020.
Recent Accounting Pronouncements
See Note 2, Significant Accounting
Policies, to the unaudited
Condensed Consolidated Financial Statements in Item 1 of Part I of
this Quarterly Report for a description of recent accounting
pronouncements and accounting changes.
How We Operate
We have continuing sales of two basic types: sales via ad-hoc
purchase orders of mostly standard product configurations (our
“turns” business) and the more challenging and
potentially more rewarding business of customer product
development. In this latter type of business, we work with
customers to help them determine optical specifications and even
create certain optical designs for them, including complex
multi-component designs that we call “engineered
solutions.” This is followed by “sampling” small
numbers of the product for the customers’ test and
evaluation. Thereafter, should a customer conclude that our
specification or design is the best solution to their product need;
we negotiate and “win” a contract (sometimes called a
“design win”) – whether of a “blanket
purchase order” type or a supply agreement. The strategy is
to create an annuity revenue stream that makes the best use of our
production capacity, as compared to the turns business, which is
unpredictable and uneven. This annuity revenue stream can also
generate low-cost, high-volume type orders. A key business
objective is to convert as much of our business to the design win
and annuity model as is possible. We face several challenges in
doing so:
●
Maintaining an
optical design and new product sampling capability, including a
high-quality and responsive optical design engineering
staff;
●
The fact that as
our customers take products of this nature into higher volume,
commercial production (for example, in the case of molded optics,
this may be volumes over one million pieces per year) they begin to
focus on reducing costs – which often leads them to turn to
larger or overseas producers, even if sacrificing quality;
and
22
●
Our small business
mass means that we can only offer a moderate amount of total
productive capacity before we reach financial constraints imposed
by the need to make additional capital expenditures – in
other words, because of our limited cash resources and cash flow,
we may not be able to service every opportunity that presents
itself in our markets without arranging for such additional capital
expenditures.
Despite these challenges to winning more “annuity”
business, we nevertheless believe we can be successful in procuring
this business because of our unique capabilities in optical design
engineering that we make available on the merchant market, a market
that we believe is underserved in this area of service offering.
Additionally, we believe that we offer value to some customers as a
source of supply in the U.S. should they be unwilling to commit to
purchase their supply of a critical component from foreign merchant
production sources. For information regarding revenue recognition
related to our various revenue streams, refer to
Critical
Accounting Policies and Estimates in our Annual Report on Form 10-K dated June 30,
2020.
Our Key Performance Indicators:
Typically, on a weekly basis, management reviews a number of
performance indicators, both qualitative and quantitative. These
indicators change from time to time as the opportunities and
challenges in the business change. These indicators are used to
determine tactical operating actions and changes. We believe that
our non-financial production indicators, such as those noted, are
proprietary information.
Financial indicators that are considered key and reviewed regularly
are as follows:
●
Sales
backlog;
●
Revenue
dollars and units by product group; and
●
Other
key indicators.
These indicators are also used to determine tactical operating
actions and changes and are discussed in more detail below.
Management is evaluating these key indicators as we transition to
our new strategic plan, and is implementing certain changes and
updates as further described below.
Sales Backlog
We believe our sales growth has been and continues to be our best
indicator of success. Our best view into the efficacy of our sales
efforts is in our “order book.” Our order book equates
to sales “backlog.” It has a quantitative and a
qualitative aspect: quantitatively, our backlog’s prospective
dollar value and qualitatively, what percent of the backlog is
scheduled by the customer for date-certain delivery. Historically,
we evaluated our backlog on a 12-month basis, which examined orders
required by a customer for delivery within a one-year period. To
better align with our strategic focus on longer-term customer
orders and relationships, beginning in fiscal 2021, we are now
evaluating our total backlog, which includes all firm orders
requested by a customer that are reasonably believed to remain in
the backlog and convert into revenues. This includes customer
purchase orders and may include amounts under supply contracts if
they meet the aforementioned criteria. Generally, a higher total
backlog is better for us.
Our total backlog at September 30, 2020 was approximately $20.9
million, an increase of 26%, as compared to $16.6 million as of
September 30, 2019. Compared to the end of fiscal 2020, however,
our total backlog decreased by 5% during the first quarter of
fiscal 2021. Backlog growth rates for the last five fiscal quarters
are:
Quarter
|
Total
Backlog ($ 000)
|
Change
From Prior Year End
|
Change
From Prior Quarter End
|
Q1 2020
|
$16,567
|
-9%
|
-9%
|
Q2 2020
|
$22,559
|
24%
|
36%
|
Q3 2020
|
$22,772
|
26%
|
1%
|
Q4 2020
|
$21,908
|
21%
|
-4%
|
Q1 2021
|
$20,866
|
-5%
|
-5%
|
The majority of the decrease in our backlog from the fourth quarter
of fiscal 2020 to the first quarter of fiscal 2021 was due to the
timing of shipments against long-term contracts. These contracts
are expected to renew in future quarters, which may substantially
increase backlog levels at the time the orders are received, and
the total backlog will subsequently be drawn down as shipments are
made against these orders.
We continue to experience strong demand for infrared products used
in the industrial, defense and first responder sectors. Over the
last several quarters, demand for medical applications, including
fever detection, has driven some of the increased demand for
infrared products. Demand for infrared products continues to be
fueled by interest in lenses made with our new BD6 material. We
expect to maintain moderate growth in our visible PMO product group
by continuing to diversify and offer new applications, with a cost
competitive structure. Over the past several years, we have
broadened our capabilities to include additional glass types and
the ability to make much larger lenses, providing long-term
opportunities for our technology roadmap and market share
expansion. Based on our backlog and recent quote activity, we
expect increases in revenue from sales of both molded and turned
infrared products and visible PMO products for the remainder of
fiscal 2021.
23
Revenue Dollars and Units by Product Group
The following table sets forth revenue dollars and units for our
three product groups for the three-month periods ended September
30, 2020 and 2019:
|
(unaudited)
Three
Months Ended September 30,
|
|
|
|
2020
|
2019
|
Quarter % Change
|
Revenue
|
|
|
|
PMO
|
$4,293,603
|
$3,184,458
|
35%
|
Infrared
Products
|
4,724,504
|
3,959,625
|
19%
|
Specialty
Products
|
490,865
|
407,847
|
20%
|
Total
revenue
|
$9,508,972
|
$7,551,930
|
26%
|
|
|
|
|
Units
|
|
|
|
PMO
|
1,126,777
|
568,730
|
98%
|
Infrared
Products
|
178,922
|
65,057
|
175%
|
Specialty
Products
|
9,633
|
8,917
|
8%
|
Total
units
|
1,315,332
|
642,704
|
105%
|
Our revenue increased by approximately $2 million for the first
quarter of fiscal 2021, as compared to the same period of the prior
fiscal year, primarily driven increases in both PMO and infrared
product sales.
Revenue generated by the PMO product group during the first quarter
of fiscal 2021 was $4.3 million, an increase of approximately $1.1
million, or 35%, as compared to the same period of the prior fiscal
year. The increase in revenue is attributed to increases in sales
to customers in the telecommunications market related to 5G
infrastructure equipment, as well as the commercial and defense
markets. Sales of PMO units increased by 98%, as compared to the
same period of the prior fiscal year, however, average selling
prices decreased 32%, due to the significant increase in
telecommunications products sales, which typically have higher
volumes and lower average selling prices. The unit volume for
telecommunications products increased by approximately 160% for the
first quarter of fiscal 2021, as compared to the same period of the
prior fiscal year.
Revenue generated by the infrared product group during the first
quarter of fiscal 2021 was $4.7 million, an increase of
approximately $765,000, or 19%, as compared to the same period of
the prior fiscal year. The increase in revenue is attributed to
increases in sales to customers in the commercial, industrial, and
defense markets. During the first quarter of fiscal 2021, sales of
infrared units increased by 175%, as compared to the prior year
period, and average selling prices decreased 57%. The increase in
units and decrease in average selling prices are driven by an
increase in sales of molded infrared products, including products
made with our new BD6 material, which are higher in volume and
lower in prices than diamond-turned infrared products. The
increased demand for molded infrared products continues to be
driven in large part by fever detection products as a result of the
ongoing COVID-19 pandemic. Although
the demand has leveled off since the initial spike, it remains
elevated. Demand for industrial applications,
firefighting cameras, and other public safety applications,
including thermal imaging assemblies, continues to be strong.
Sales of diamond-turned infrared products also increased compared
to the first quarter of fiscal 2020, primarily due to the timing of
order shipments against a large-volume annual contract, for which
shipments were lower in the first quarter of fiscal
2020.
In the first quarter of fiscal 2021, our specialty products revenue
increased by $83,000, or 20%, as compared to the same period of the
prior fiscal year, primarily due to increased sales of collimator
assemblies to customers in the industrial and commercial
markets.
Other Key Indicators
Other key indicators include various operating metrics, some of
which are qualitative and others are quantitative. These indicators
change from time to time as the opportunities and challenges in the
business change. They are mostly non-financial indicators, such as
evaluating the pipeline of sales opportunities, on time delivery
trends, units of shippable output by major product line, production
yield rates by major product line, and the output and yield data
from significant intermediary manufacturing processes that support
the production of the finished shippable product. These indicators
can be used to calculate such other related indicators as
fully-yielded unit production per-shift, which varies by the
particular product and our state of automation in production of
that product at any given time. Higher unit production per shift
means lower unit cost and, therefore, improved margins or improved
ability to compete, where desirable, for price sensitive customer
applications. The data from these reports is used to determine
tactical operating actions and changes. Management also assesses
business performance and makes business decisions regarding our
operations using certain non-GAAP measures. These non-GAAP measures
are described in more detail below under the heading
“Non-GAAP Financial Measures.”
24
Non-GAAP Financial
Measures
We report our historical results in accordance with GAAP; however,
our management also assesses business performance and makes
business decisions regarding our operations using certain non-GAAP
financial measures. We believe these non-GAAP financial measures
provide useful information to management and investors that is
supplementary to our financial condition and results of operations
computed in accordance with GAAP; however, we acknowledge that our
non-GAAP financial measures have a number of limitations. As such,
you should not view these disclosures as a substitute for results
determined in accordance with GAAP, and they are not necessarily
comparable to non-GAAP financial measures that other companies
use.
EBITDA
EBITDA is a non-GAAP financial measure used by management, lenders,
and certain investors as a supplemental measure in the evaluation
of some aspects of a corporation's financial position and core
operating performance. Investors sometimes use EBITDA, as it allows
for some level of comparability of profitability trends between
those businesses differing as to capital structure and capital
intensity by removing the impacts of depreciation and amortization.
EBITDA also does not include changes in major working capital
items, such as receivables, inventory and payables, which can also
indicate a significant need for, or source of, cash. Since
decisions regarding capital investment and financing and changes in
working capital components can have a significant impact on cash
flow, EBITDA is not necessarily a good indicator of a business's
cash flows. We use EBITDA for evaluating the relative underlying
performance of our core operations and for planning purposes. We
calculate EBITDA by adjusting net income to exclude net interest
expense, income tax expense or benefit, depreciation and
amortization, thus the term “Earnings Before Interest, Taxes,
Depreciation and Amortization” and the acronym
“EBITDA.”
We believe EBITDA is helpful for investors to better understand our
underlying business operations. The following table adjusts net
income (loss) to EBITDA for the three months ended September 30,
2020 and 2019:
|
(unaudited)
|
|
|
Three
Months Ended September 30,
|
|
|
2020
|
2019
|
Net
income (loss)
|
$97,068
|
$(1,375,157)
|
Depreciation
and amortization
|
826,308
|
892,072
|
Income
tax provision
|
434,640
|
148,318
|
Interest
expense
|
58,549
|
98,541
|
EBITDA
|
$1,416,565
|
$(236,226)
|
%
of revenue
|
15%
|
-3%
|
Our EBITDA for the three months ended September 30, 2020 was
approximately $1.4 million, compared to an EBITDA loss of
approximately $236,000 for the three months ended September 30,
2019. The increase in EBITDA in
the first quarter of fiscal 2021 was primarily due the increase in
revenue, resulting in higher gross margin and operating income, as
compared to the same period of the prior fiscal year. In addition,
there was a favorable difference of approximately $400,000 in
foreign currency transaction losses.
Item 4. Controls and
Procedures
Under
the supervision and with the participation of our management,
including our Chief Executive Officer and our Chief Financial
Officer, we evaluated the effectiveness of the design and operation
of our disclosure controls and procedures (as defined in Rule
13a-15(e) under the Exchange Act) as of September 30, 2020, the end
of the period covered by this report. Based on that evaluation, the
Chief Executive Officer and Chief Financial Officer concluded that
our disclosure controls and procedures were effective as of
September 30, 2020 in reporting on a timely basis information
required to be disclosed by us in the reports we file or submit
under the Exchange Act.
During the fiscal quarter ended September 30, 2020, there was no
change in our internal control over financial reporting (as defined
in Rule 13a-15(f) under the Exchange Act) that has materially
affected, or is reasonably likely to materially affect, our
internal control over financial reporting.
25
PART II OTHER INFORMATION
Item 1. Legal
Proceedings
None
Item 2. Unregistered Sales of Equity
Securities and Use of Proceeds
None
Item 3. Defaults Upon Senior
Securities
None
Item 4. Mine Safety
Disclosures
None
Item 5. Other Information
None
26
Item 6. Exhibits
The following exhibits are filed herewith as a part of this
report.
Exhibit Number
|
Description |
|
|
|
|
Certificate of Incorporation of LightPath Technologies, Inc., filed
June 15, 1992 with the Secretary of State of Delaware, which was
filed as Exhibit 3.1.1 to our Annual Report on Form 10-K (File No.
000-27548) filed with the Securities and Exchange Commission on
September 10, 2020, and is incorporated herein by reference
thereto.
|
||
|
|
|
Certificate of Amendment to Certificate of Incorporation of
LightPath Technologies, Inc., filed October 2, 1995 with the
Secretary of State of Delaware, which was filed as Exhibit 3.1.2 to
our Annual Report on Form 10-K (File No. 000-27548) filed with the
Securities and Exchange Commission on September 10, 2020, and is
incorporated herein by reference thereto.
|
||
|
|
|
Certificate of Designations of Class A common stock and Class E-1
common stock, Class E-2 common stock, and Class E-3 common stock of
LightPath Technologies, Inc., filed November 9, 1995 with the
Secretary of State of Delaware, which was filed as Exhibit 3.1.3 to
our Annual Report on Form 10-K (File No. 000-27548) filed with the
Securities and Exchange Commission on September 10, 2020, and is
incorporated herein by reference thereto.
|
||
|
|
|
Certificate of Designation of Series A Preferred Stock of LightPath
Technologies, Inc., filed July 9, 1997 with the Secretary of State
of Delaware, which was filed as Exhibit 3.4 to our Annual Report on
Form 10-KSB40 filed with the Securities and Exchange Commission on
September 11, 1997, and is incorporated herein by reference
thereto.
|
||
|
|
|
Certificate of Designation of Series B Stock of LightPath
Technologies, Inc., filed October 2, 1997 with the Secretary of
State of Delaware, which was filed as Exhibit 3.2 to our Quarterly
Report on Form 10-QSB (File No. 000-27548) filed with the
Securities and Exchange Commission on November 14, 1997, and is
incorporated herein by reference thereto.
|
||
|
|
|
Certificate of Amendment of Certificate of Incorporation of
LightPath Technologies, Inc., filed November 12, 1997 with the
Secretary of State of Delaware, which was filed as Exhibit 3.1 to
our Quarterly Report on Form 10-QSB (File No. 000-27548) filed with
the Securities and Exchange Commission on November 14, 1997, and is
incorporated herein by reference thereto.
|
||
|
|
|
Certificate of Designation of Series C Preferred Stock of LightPath
Technologies, Inc., filed February 6, 1998 with the Secretary of
State of Delaware, which was filed as Exhibit 3.2 to our
Registration Statement on Form S-3 (File No. 333-47905) filed with
the Securities and Exchange Commission on March 13, 1998, and is
incorporated herein by reference thereto.
|
||
|
|
|
Certificate of Designation, Preferences and Rights of Series D
Participating Preferred Stock of LightPath Technologies, Inc. filed
April 29, 1998 with the Secretary of State of Delaware, which was
filed as Exhibit 1 to our Registration Statement on Form 8-A (File
No. 000-27548) filed with the Securities and Exchange Commission on
April 28, 1998, and is incorporated herein by reference
thereto.
|
||
|
|
|
Certificate of Designation of Series F Preferred Stock of LightPath
Technologies, Inc., filed November 2, 1999 with the Secretary of
State of Delaware, which was filed as Exhibit 3.2 to our
Registration Statement on Form S-3 (File No: 333-94303) filed with
the Securities and Exchange Commission on January 10, 2000, and is
incorporated herein by reference thereto.
|
||
|
|
|
|
Certificate of Amendment of Certificate of Incorporation of
LightPath Technologies, Inc., filed February 28, 2003 with the
Secretary of State of Delaware, which was filed as Appendix A to
our Proxy Statement (File No. 000-27548) filed with the Securities
and Exchange Commission on January 24, 2003, and is incorporated
herein by reference thereto.
|
|
|
||
Certificate of Amendment of Certificate of Incorporation of
LightPath Technologies, Inc., filed March 1, 2016 with the
Secretary of State of Delaware, which was filed as Exhibit 3.1.11
to our Quarterly Report on Form 10-Q (File No: 000-27548) filed
with the Securities and Exchange Commission on November 14, 2016,
and is incorporated herein by reference thereto.
|
27
Certificate of Amendment of Certificate of Incorporation of
LightPath Technologies, Inc., filed October 30, 2017 with the
Secretary of State of Delaware, which was filed as Exhibit 3.1 to
our Current Report on Form 8-K (File No: 000-27548) filed with the
Securities and Exchange Commission on October 31, 2017, and is
incorporated herein by reference thereto.
|
||
|
|
|
Certificate of Amendment of Certificate of Designations of Class A
Common Stock and Class E-1 Common Stock, Class E-2 Common Stock,
and Class E-3 Common Stock of LightPath Technologies, Inc., filed
October 30, 2017 with the Secretary of State of Delaware, which was
filed as Exhibit 3.2 to our Current Report on Form 8-K (File No:
000-27548) filed with the Securities and Exchange Commission on
October 31, 2017, and is incorporated herein by reference
thereto.
|
||
|
|
|
Certificate of Amendment of Certificate of Designation, Preferences
and Rights of Series D Participating Preferred Stock of LightPath
Technologies, Inc., filed January 30, 2018 with the Secretary of
State of Delaware, which was filed as Exhibit 3.1 to our Current
Report on Form 8-K (File No: 000-27548) filed with the Securities
and Exchange Commission on February 1, 2018, and is incorporated
herein by references thereto.
|
||
|
|
|
Amended and Restated Bylaws of LightPath Technologies, Inc., which
was filed as Exhibit 3.1 to our Current Report on Form 8-K (File
No: 000-27548) filed with the Securities and Exchange Commission on
February 3, 2015, and is incorporated herein by reference
thereto.
|
||
|
|
|
First Amendment to Amended and Restated Bylaws of LightPath
Technologies, Inc., which was filed as Exhibit 3.1 to our Current
Report on Form 8-K (File No: 000-27548) filed with the Securities
and Exchange Commission on September 21, 2017, and is incorporated
herein by reference thereto.
|
||
|
|
|
Certification of Chief Executive Officer pursuant to Rule 13a-14(a)
of the Securities Exchange Act of 1934*
|
|
|
|
|
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(a)
of the Securities Exchange Act of 1934*
|
|
|
|
|
|
Certification of Chief Executive Officer pursuant to 18 U.S.C.
Section 1350 of Chapter 63 of Title 18 of the United States
Code*
|
|
|
|
|
|
Certification of Chief Financial Officer pursuant to 18 U.S.C.
Section 1350 of Chapter 63 of Title 18 of the United States
Code*
|
|
|
|
|
|
101.INS
|
XBRL Instance Document*
|
|
|
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document*
|
|
|
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase
Document*
|
|
|
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase
Document*
|
|
|
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase
Document*
|
|
|
|
|
101.PRE
|
XBRL Taxonomy Presentation Linkbase Document*
|
|
*filed herewith
28
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly
authorized.
|
LIGHTPATH TECHNOLOGIES, INC.
|
|
|
|
|
|
|
Date: November 5, 2020
|
By:
|
/s/
Shmuel Rubin
|
|
|
|
Shmuel Rubin
|
|
|
|
President and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
Date: November 5, 2020
|
By:
|
/s/
Donald O. Retreage, Jr.
|
|
|
|
Donald O. Retreage, Jr.
|
|
|
|
Chief Financial Officer
|
|
29